Quarterly Changes to the NASDAQ Q-50 Index Sep 12, 2009
As a result of the evaluation, the following eight securities will be removed from the Index: Career Education Corporation (Nasdaq: - ), Gentex Corporation (Nasdaq: - ), Gen-Probe Incorporated (Nasdaq: - ), Leap Wireless International, Inc. (Nasdaq: - ), Lincoln Electric Holdings, Inc. (Nasdaq: - ), OSI Pharmaceuticals Inc. (Nasdaq: - ), Patterson-UTI Energy, Inc. (Nasdaq: - ), and VCA Antech, Inc. (Nasdaq: - ). The NASDAQ Q-50 Index is the basis for the PowerShares NXQ Portfolio (Fund) (Nasdaq:... (Primezone Releases)
Some companies left behind in bull's dust Aug 12, 2009
Real solutions for your real estate needs. Choose from the selections below. (USA Today -- Money)
Sanofi-Aventis could increase ophthalmology footprint with Allergan seen as strong candidate Aug 7, 2009
The fact that David Guyer is currently chairman of the board of Lux already sets M&A implications, as he sold Eyetech Pharmaceuticals to OSI Pharmaceuticals (NASDAQ:OSIP) for USD 935m in 2005, the person added. The CEO disclosed that Lux is working with a group, when asked if it had retained a bank. (FT.com -- Markets)
Roche says half-year profit down 29 percent Jul 23, 2009
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of Tarceva (erlotinib), met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva immediately after initial chemotherapy. A statistically significant improvement in overall survival was seen in this pre-planned final analysis of the total patient population. (Fresno Bee -- Business)
Ambrilia Enters Into an Agreement for the Sale of PCK3145 Jul 17, 2009
Dr. Bacopoulos has served as head of the Cancer Research Group at Pfizer Inc, President of OSI Pharmaceuticals Inc., C.E.O. of Aton Pharma Inc. and was involved in managing the development of Tarceva. and Zolinza. (CCNMatthews Press Releases)
OSI Pharmaceuticals Jul 14, 2009
Local Search Site Search. THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING. (Boston Globe)
OSI Pharmaceuticals to shut Boulder office Jul 9, 2009
OSI Pharmaceuticals to close Boulder office - Denver Business Journal ... OSI Pharmaceuticals to close Boulder office. (Denver Business Journal, CO)
Human Genome Scientist Collins Is Said to Be Leading Candidate to Run NIH May 23, 2009
That work led to the development of new drugs, such as Takeda Pharmaceutical Co.s Velcade as well as Roche Holding AG and OSI Pharmaceuticals Inc.s Tarceva, both for cancer. The race to map the genome pitted Collins and his team against a rival private company, Celera Genomics Group, led by. (Bloomberg -- US)
Firms to Release Cancer Findings at Conf. May 14, 2009
TO), ArQule Inc. (ARQL), Bristol-Myers Squibb Co. (BMY), (CGRB), Exelixis Inc. (EXEL), Eli Lilly & Co. (LLY), OSI Pharmaceuticals Inc. (OSIP), Roche Holding AG (RHHBY), (ROG.VX), (CH001203), (JP347535), (US04269E), (US110122), (US222083), (US30161Q), (US532457), (US671040), ) at SmartMoney ... Thursday's release includes much-anticipated updates from companies like Roche Holding AG's (RHHBY) Genentech unit, OSI Pharmaceuticals Inc. (OSIP) and Exelixis Inc. (EXEL) ... Tarceva, sold by OSI... (SmartMoney)
Growth in All the Wrong Places May 9, 2009
Royalties in and of themselves aren't bad -- Gilead Sciences (Nasdaq: GILD) gets them from Roche for Tamiflu and royalties have become an integral strategy for OSI Pharmaceuticals (Nasdaq: OSIP), which receives them from Roche for ex-U.S. sales of Tarceva and for patents that cover diabetes drugs made by Merck (NYSE: MRK), Novartis (NYSE: NVS), and Bristol-Myers Squibb (NYSE: BMY). But clearly Onyx would prefer growth to come from places where it gets a higher portion of sales. (MSNBC -- Business)
Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS Apr 7, 2009
This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec. The company's lead product, AV-951, a potential best-in-class triple VEGF receptor inhibitor, is completing Phase 2 clinical development in patients with metastatic renal cell cancer and is expected to enter Phase 3... (EurekAlert!)
Taxing the Alphabet, and Other Top Stories Mar 21, 2009
In other CourtTV news, OSI Pharmaceuticals demands that Teva Pharmaceutical Industries (Nasdaq: TEVA) and Mylan (NYSE: MYL) be banned from selling their generic version of cancer pill Tarceva, alleging it infringes on three OSI patents. If unsuccessful, OSI will face direct competition for its $457 million in 2008 U.S.-only Tarceva sales -- and that could affect its goal of reaching the $2 billion mark in worldwide sales it envisions hitting in 2011. (MSNBC -- Business)
Standard & Poor's Announces Changes to U.S. Indices Mar 6, 2009
OSI Pharmaceuticals Inc. (Nasdaq: ) will replace Ferro Corp. (NYSE: ) in the S&P MidCap 400 after the close of trading on Thursday, March 12 ... OSI Pharmaceuticals is a biotechnology company. (PR Newswire)
